Respiratory Syncytial Virus (RSV) Market Explosion To hit USD$2.4 billion by 2030 | Most Leading Companies - AstraZeneca, Bausch Health Companies, Bavarian Nordic, Moderna, Inc., and mAbxience,

DataM Intelligence has published a new research report on "Respiratory Syncytial Virus Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

The average cost of a single palivizumab dose ranges from $1,660 for infants under 6 months to $2,500 for children in their second year. Immunoprophylaxis with palivizumab costs approximately $302,000 to prevent one RSV-related hospitalization in otherwise healthy preterm infants under 6 months, which may limit the global RSV market's growth.

According to NIAID, RSV is the leading cause of bronchiolitis (inflammation of the tiny airways in the lungs) among infants under one year old in the United States, accounting for roughly 58,000 hospitalisations each year. RSV infection is expected to kill approximately 14,000 persons over the age of 65 in the United States each year. RSV affects an estimated 64 million people worldwide and kills 160,000 people each year. These are the specific aspects that drive market expansion.

According to NIAID, RSV is the leading cause of bronchiolitis in U.S. infants under one, causing ~58,000 hospitalizations annually, and kills ~14,000 Americans over 65 each year. Globally, RSV affects ~64 million people and causes 160,000 deaths annually-key factors driving market growth.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/respiratory-syncytial-virus-market?kb

United States: Expanded Vaccine Access

✅ In June 2025, the FDA expanded approval for Moderna's RSV vaccine, mResvia, to include adults aged 18-59 at increased risk, complementing earlier approvals for those 60 and older.

✅ The CDC's Advisory Committee on Immunization Practices (ACIP) recommended Merck's monoclonal antibody, clesrovimab (Enflonsia), for infants under 8 months during their first RSV season, offering an alternative to nirsevimab.

Japan: Strategic Vaccine Rollouts

✅ GSK's RSV vaccine, Arexvy, received approval in 2024 for adults aged 60 and older. In June 2025, the Ministry of Health, Labour and Welfare accepted a regulatory application to expand its use to adults aged 18-49 at increased risk.

✅ Sanofi aims to include its RSV monoclonal antibody, Beyfortus, in Japan's National Immunization Program by 2026, pending regulatory approvals.

South Korea: Strengthening Infant Protection

✅ SK bioscience commenced the administration of its RSV preventive antibody for infants under 12 months for the 2025-2026 season, enhancing protection during the RSV season.

✅ In April 2024, Korea approved nirsevimab for infants, providing a long-acting monoclonal antibody option for RSV prevention.

Key Players:

Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., and mAbxience, among others.

Key Development:

On May 3, 2023, GSK plc announced that the U.S. FDA approved Arexvy, an adjuvanted RSV vaccine, for preventing lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older. This marks the world's first RSV vaccine approved for older adults.

Growth Forecast Projected:
The Global Respiratory Syncytial Virus Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Respiratory Syncytial Virus Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market

Key Segments:

By Drug Type: (Ribavirin, Nirsevimab, Virazole, Palivizumab, Riba Tab, Others)

By Dosage Form: (Oral, Injectable, Inhaler, Others)

By Treatment Type: (Immune prophylaxis, Supportive care, Antiviral Medications)

By Distribution Channel: (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Respiratory Syncytial Virus producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Respiratory Syncytial Virus revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/respiratory-syncytial-virus-market?kb

FAQ's

Q1: What is the current size of the Respiratory Syncytial Virus Market?

A: The Respiratory Syncytial Virus Market stood at USD 1.2 billion in 2022 and is set to experience remarkable growth, reaching USD 2.4 billion by 2030

Q2: How fast is the Respiratory Syncytial Virus Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 10.2% from 2025 to 2032

Q3: Which regions are dominating the Respiratory Syncytial Virus Market and which are fastest-growing?

A: North America is projected to account for approximately 39.4% of the total market share over the forecast period.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/respiratory-syncytial-virus-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.